文献速递血栓与止血

穿越肾衰竭中的止血悖论:实用综述

Navigating through the haemostatic paradox in kidney failure: A practical overview.
PubMed 文献 · Br J Haematol · 2023-06-04

慢性肾脏病(CKD)全球患病率约9.1%,部分患者需透析替代治疗。CKD患者出血与血栓风险并存且管理困难,针对抗血小板药和抗凝药的研究极少、证据非常有限。本综述阐述终末期肾病患者止血基础科学现状,并转化至临床常见止血挑战及现有证据与指导。

要点

  • CKD影响全球约9.1%人口,部分患者因完全肾衰竭需透析替代治疗。
  • CKD患者出血与血栓风险均增加且常共存,临床管理困难。
  • 抗血小板药和抗凝药在该脆弱亚组的研究极少,证据非常有限。

核心结论

  • 综述旨在解释终末期肾病患者止血基础科学的最新现状,并转化至临床常见止血挑战及现有证据与指导。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • CKD影响全球约9.1%人口,造成显著健康负担,部分患者因完全肾衰竭需透析替代治疗。
  • CKD患者出血与血栓风险均增加,两者常共存,管理困难。
  • 针对该脆弱亚组的抗血小板药和抗凝药研究极少,证据非常有限。

局限性

  • 原文述针对该亚组的抗血小板药和抗凝药研究极少,证据非常有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) affects around 9.1% of humankind globally resulting in a significant health burden. Some of these individuals will also require renal replacement therapy with dialysis due to complete kidney failure. Patients with CKD are known to be at increased risk of both bleeding and thrombosis. Often it is very difficult to manage these yin and yang since both risks tend to co-exist. Clinically, very few studies have looked at the effects of antiplatelet agents and anticoagulants in this highly vulnerable subgroup of medical patients and evidence is very limited. This review attempts to explain the current state-of-the-art regarding the basic science of haemostasis in patients with end-stage kidney disease. We also try to transfer this knowledge into the clinics by looking at some common haemostasis challenges that are encountered in this cohort of patients and what evidence and guidance there is for their optimal management.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Caruana J, Riva N, Vella K, et al. Navigating through the haemostatic paradox in kidney failure: A practical overview. Br J Haematol. 2023. PMID: 37271168. doi:10.1111/bjh.18903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。